352 Views

Advancing Care for Women With HER2+ Metastatic Breast Cancer

Sunday, November 6, 2022

Location: On-Demand

CE: .75 credit/contact hour

Speaker(s)

Discuss the evidence base underlying recent important updates to clinical practice guidelines related to second-line treatment of patients with metastatic HER2-positive breast cancer.
Interpret the practical relevance of data from clinical trials of emerging biomarkers and HER2-targeted therapies.
Follow best practices for monitoring and managing side effects associated with novel HER2-targeted agents when caring for patients with metastatic HER2-positive breast cancer.